Technology collaboration – TODE20150318001 OFFER
Scientists at a German university developed compounds to treat neoplastic diseases or proliferative disorders, such as chronic lymphocytic leukemia (CLL). In tests on different CLL populations the compounds show a high selectivity towards neoplastic cells. The activity was proven in a xenograft model of CLL. Licensees from the pharmaceutical industry are sought.
Powered by WPeMatico